Anthem Biosciences IPO

About Anthem Biosciences IPO

The initial public offering (IPO) of Anthem Biosciences Ltd is a bookbuilding exercise, with an offer for sale with equity shares of face value of ₹2, aggregating up to ₹3,395 crore. The price band is set at ₹540 to ₹570. The lot size of the IPO is 26.

The IPO opens on July 14, 2025, and closes on July 16, 2025. The share allotment for Anthem IPO will be on July 17, 2025. The credit of shares to the demat account will take place on July 18, 2025, with the same date being for the initiation of refunds. Anthem Biosciences IPO will be listed on BSE and NSE, with July 21, 2025, being the listing date.

Anthem Biosciences is a leading innovation-driven CRDMO (Contract Research, Development and Manufacturing Organization) with fully integrated operations across NCE and NBE drug development. The company is among the few in India with advanced platforms such as RNAi, ADCs, mAbs, peptides, and lipids, and has achieved over ₹10,000 crore in revenue within just 14 years of operations. It also recorded the highest revenue growth in FY23–24 among Indian and global peers, according to the F&S Report.

Objectives of Anthem Biosciences IPO

The company will not receive any proceeds from the offer. All proceeds, after deducting expenses and taxes, will go to the Selling Shareholders. The company sees enhancing visibility, brand image, and liquidity in the public market as listing benefits.

Industry Outlook

• Government initiatives like the PLI Scheme, Make in India, and Bulk Drug Parks have been driving domestic drug manufacturing, thus boosting India’s potential as a global pharma hub and increasing CRDMOs.

• India allows up to 100% FDI in pharmaceuticals, allowing for the development of infrastructure and capabilities. FDI in the sector grew at a CAGR of 31.6% from USD 18 billion in FY2019 to USD 54 billion in FY2023.

• India has more than 3,000 drug companies, 10,500 manufacturing units, and the highest number of US FDA-approved plants outside the US, hinting at a strong manufacturing base.

• Manufacturing costs are 30-40% lower in India, when compared to those in the US or Europe. This makes it an attractive outsourcing destination.

• Many companies are diversifying supply chains to reduce their dependency on China, boosting India’s position as an alternative manufacturing hub.

Anthem Biosciences IPO Information

Anthem Biosciences Ltd. is a leading Contract Research, Development, and Manufacturing Organisation (CRDMO) with integrated operations across drug discovery, development, and manufacturing. One of India’s fastest-growing CRDMOs, it reached ₹1,000 crore in revenue within 14 years in Fiscal 2021 and recorded the highest growth among peers in Fiscal 2023-24.

The company excels in both small and large molecule drug development, offering services across New Chemical Entity (NCE) and New Biological Entity (NBE) lifecycles. Its expertise spans advanced modalities like RNAi, ADCs, peptides, lipids, and oligonucleotides, with pioneering work in ADC linkers and monoclonal antibody payloads.

Operating in CRDMO services and specialty ingredients, the company supports regulated markets with end-to-end drug development while leveraging fermentation and biocatalysis for probiotics, enzymes, peptides, and biosimilars. With cutting-edge technology and a customer-centric approach, it remains at the forefront of pharmaceutical innovation.

IPO Registrar and Book Running Lead Manager

Registrar - KFIN Technologies Limited

Book Running Lead Managers – JM Financial Limited, Citigroup Global Markets India Private Limited, JP Morgan India Private Limited, Nomura Financial Advisory and Securities (India) Private Limited

Business Model

Anthem Biosciences is a leading CRDMO in India, specialising in ADCs, RNAi, peptides, and oligonucleotides. With expertise in bio-catalysis and biosynthesis, Anthem provides tailored solutions for custom synthesis and chemical manufacturing, making it a preferred partner for large pharmaceutical and biotech firms. It caters to small pharmaceutical and biotech companies, six of which have been acquired by major pharmaceutical firms. Anthem also supports a large pharmaceutical company with CDMO services for three blockbuster molecules.

Company Growth Trajectory

Anthem Biosciences is one of the youngest and fastest-growing Indian CRDMO companies, reaching ₹1,000 crore in revenue within 14 years by FY2021. It recorded the highest revenue growth among Indian and global peers between FY23 and FY24, with sales, EBITDA, and net profit growing at CAGRs of 22.1%, 29.5%, and 41.0% from 2020 to 2024.

In FY24, Anthem achieved the highest RoCE, RoE, and gross fixed asset turnover among its Indian peers, reflecting strong operational efficiency. It also ranked second in employee productivity, with an average revenue per employee of ₹0.778 crore in FY24.

How to Check Allotment Status of Anthem Biosciences IPO?

1. Visit the Registrar's Website

Go to the official website of KFin Technologies, the registrar for this IPO. KFin's website has a page for checking IPO allotment status. On this page, enter your Permanent Account Number (PAN), application number, or Demat account ID. Then click the 'Submit' button. Your allotment status will be displayed.

The KFin IPO allotment status page is: https://ris.kfintech.com/ipostatus/

2. Check on the Bombay Stock Exchange Website

The Bombay Stock Exchange (BSE) also has an IPO allotment status page. Go to www.bseindia.com and find the 'Investors' tab. Under 'Investors', click on 'IPO'. This will take you to the IPO allotment status page.

On the BSE IPO page, follow these steps:

• Select 'Equity' from the dropdown menu
• Choose ‘Anthem Biosciences Ltd.’ in the next dropdown
• Enter your application number
• Enter your PAN
• Click 'Search'

Your Anthem Biosciences Ltd IPO allotment status will be displayed.

1. Verify on the National Stock Exchange Website

The National Stock Exchange (NSE) has an IPO Bid Verification module. Use this to check Anthem Biosciences Ltd. IPO allotment status.

Go to www.nseindia.com and find the 'Invest' tab. Click on 'Verify IPO Bids' under 'Resources & Tools'.

On the NSE IPO Bid Verification page, enter:

• Application number
• PAN

Then click 'Submit'. Your Anthem Biosciences Ltd IPO bid and allotment details will be displayed.

How to Apply for Anthem Biosciences IPO?

Here are the steps to apply for Anthem Biosciences IPO:

• Step 1: Log in to your Kotak Neo Demat account - Log in to your Demat account to access IPO investments. Next, select the current IPO section.
• Step 2: Specify IPO details - Enter the number of lots and the price you wish to apply for.
• Step 3: Enter UPI ID - After entering your UPI ID, click submit. This will place your bid with the exchange.
• Step 4: Mandate Notification - Your UPI app will receive a mandate notification to block funds.
• Step 5: Approve Request - Your funds will be blocked once you approve the mandate request on your UPI.